Logo image of ADVM

ADVERUM BIOTECHNOLOGIES INC (ADVM) Stock Fundamental Analysis

NASDAQ:ADVM - Nasdaq - US00773U2078 - Common Stock - Currency: USD

3.26  +0.03 (+0.93%)

After market: 3.26 0 (0%)

Fundamental Rating

3

Overall ADVM gets a fundamental rating of 3 out of 10. We evaluated ADVM against 566 industry peers in the Biotechnology industry. While ADVM seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, ADVM is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ADVM has reported negative net income.
ADVM had a negative operating cash flow in the past year.
ADVM had negative earnings in each of the past 5 years.
In the past 5 years ADVM always reported negative operating cash flow.
ADVM Yearly Net Income VS EBIT VS OCF VS FCFADVM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

ADVM has a Return On Assets of -64.80%. This is in the lower half of the industry: ADVM underperforms 62.90% of its industry peers.
ADVM's Return On Equity of -164.81% is on the low side compared to the rest of the industry. ADVM is outperformed by 65.72% of its industry peers.
Industry RankSector Rank
ROA -64.8%
ROE -164.81%
ROIC N/A
ROA(3y)-63.55%
ROA(5y)-49.62%
ROE(3y)-136.88%
ROE(5y)-96.75%
ROIC(3y)N/A
ROIC(5y)N/A
ADVM Yearly ROA, ROE, ROICADVM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ADVM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADVM Yearly Profit, Operating, Gross MarginsADVM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

6

2. Health

2.1 Basic Checks

ADVM does not have a ROIC to compare to the WACC, probably because it is not profitable.
ADVM has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ADVM has been increased compared to 5 years ago.
There is no outstanding debt for ADVM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ADVM Yearly Shares OutstandingADVM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
ADVM Yearly Total Debt VS Total AssetsADVM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -9.49, we must say that ADVM is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -9.49, ADVM is not doing good in the industry: 73.50% of the companies in the same industry are doing better.
ADVM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.49
ROIC/WACCN/A
WACC9.91%
ADVM Yearly LT Debt VS Equity VS FCFADVM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 5.73 indicates that ADVM has no problem at all paying its short term obligations.
ADVM's Current ratio of 5.73 is fine compared to the rest of the industry. ADVM outperforms 61.84% of its industry peers.
ADVM has a Quick Ratio of 5.73. This indicates that ADVM is financially healthy and has no problem in meeting its short term obligations.
ADVM has a Quick ratio of 5.73. This is in the better half of the industry: ADVM outperforms 62.19% of its industry peers.
Industry RankSector Rank
Current Ratio 5.73
Quick Ratio 5.73
ADVM Yearly Current Assets VS Current LiabilitesADVM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

ADVM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 51.29%, which is quite impressive.
Looking at the last year, ADVM shows a very negative growth in Revenue. The Revenue has decreased by -72.22% in the last year.
The Revenue has been growing by 31.95% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)51.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.78%
Revenue 1Y (TTM)-72.22%
Revenue growth 3Y-48.91%
Revenue growth 5Y31.95%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 7.44% on average over the next years.
ADVM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 135.74% yearly.
EPS Next Y10.69%
EPS Next 2Y18.36%
EPS Next 3Y6.54%
EPS Next 5Y7.44%
Revenue Next Year-84.17%
Revenue Next 2Y-52.49%
Revenue Next 3Y-34.14%
Revenue Next 5Y135.74%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ADVM Yearly Revenue VS EstimatesADVM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
ADVM Yearly EPS VS EstimatesADVM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ADVM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ADVM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADVM Price Earnings VS Forward Price EarningsADVM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADVM Per share dataADVM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.36%
EPS Next 3Y6.54%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ADVM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADVERUM BIOTECHNOLOGIES INC

NASDAQ:ADVM (4/30/2025, 8:00:00 PM)

After market: 3.26 0 (0%)

3.26

+0.03 (+0.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-15 2025-04-15/bmo
Earnings (Next)05-08 2025-05-08/amc
Inst Owners68.19%
Inst Owner Change11.7%
Ins Owners11.62%
Ins Owner Change2.8%
Market Cap68.10M
Analysts82.86
Price Target23.66 (625.77%)
Short Float %8.48%
Short Ratio6.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-19.46%
Min EPS beat(2)-41.41%
Max EPS beat(2)2.5%
EPS beat(4)2
Avg EPS beat(4)-0.76%
Min EPS beat(4)-41.41%
Max EPS beat(4)40.56%
EPS beat(8)5
Avg EPS beat(8)5.77%
EPS beat(12)6
Avg EPS beat(12)-0.32%
EPS beat(16)8
Avg EPS beat(16)0.39%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-21.92%
PT rev (3m)-21.92%
EPS NQ rev (1m)-29.22%
EPS NQ rev (3m)-29.22%
EPS NY rev (1m)-5.77%
EPS NY rev (3m)-5.77%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-98.75%
Revenue NY rev (3m)-98.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 68.1
P/FCF N/A
P/OCF N/A
P/B 0.96
P/tB 0.96
EV/EBITDA N/A
EPS(TTM)-5.65
EYN/A
EPS(NY)-5.05
Fwd EYN/A
FCF(TTM)-4.44
FCFYN/A
OCF(TTM)-4.43
OCFYN/A
SpS0.05
BVpS3.39
TBVpS3.39
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -64.8%
ROE -164.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-63.55%
ROA(5y)-49.62%
ROE(3y)-136.88%
ROE(5y)-96.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.62%
Cap/Sales 38.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.73
Quick Ratio 5.73
Altman-Z -9.49
F-Score4
WACC9.91%
ROIC/WACCN/A
Cap/Depr(3y)68.65%
Cap/Depr(5y)163.27%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.78%
EPS Next Y10.69%
EPS Next 2Y18.36%
EPS Next 3Y6.54%
EPS Next 5Y7.44%
Revenue 1Y (TTM)-72.22%
Revenue growth 3Y-48.91%
Revenue growth 5Y31.95%
Sales Q2Q%N/A
Revenue Next Year-84.17%
Revenue Next 2Y-52.49%
Revenue Next 3Y-34.14%
Revenue Next 5Y135.74%
EBIT growth 1Y-0.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-49.05%
EBIT Next 3Y-28.76%
EBIT Next 5Y-27.07%
FCF growth 1Y-1.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.72%
OCF growth 3YN/A
OCF growth 5YN/A